Advancements in the Management of Ovarian Cancer - Episode 3
Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer
Panelists discuss how frontline maintenance therapy options for advanced ovarian cancer are influenced by key factors, such as a patient’s HRD status, and when a combination approach with PARP inhibitors and bevacizumab might be preferred over monotherapy.
Video content above is prompted by the following:
- Dr Chan to ask Dr Herzog: Briefly review frontline maintenance therapy options for advanced ovarian cancer and highlight the key factors that guide your choice between available therapies.
- How does a patient’s HRD status influence your selection of maintenance therapy?
- Under what circumstances would you consider a combination approach with PARP inhibitors and bevacizumab vs using monotherapy?
Related Content:
